AbstrAct
Glioblastoma is an intrinsic brain tumour thought to arise from neuroglial progenitor cells. Its incidence increases steadily with age. Males are moderately more often affected. Genetic predisposition and exposure to irradiation in childhood are the only established risk factors which, however, account only for a very small proportion of glioblastomas. Surgery as safely feasible not only to allow for tissue diagnosis but also to reduce tumour volume is usually the first therapeutic measure. Radiotherapy delivered to the tumour region with a safety margin has been demonstrated to roughly double survival four decades ago. Temozolomide given during radiotherapy followed by six cycles of maintenance chemotherapy was the first and so far only pharmacological treatment shown to prolong survival. Adding tumour-treating fields during maintenance, temozolomide chemotherapy has been reported to prolong survival. There is little evidence that any intervention at relapse improves outcome, but nitrosourea-based chemotherapy, commonly lomustine, is probably the most agreed on standard of care. Bevacizumab prolongs progression-free survival and probably quality of life in the first line or recurrent setting, but not overall survival, and is therefore not approved in the European Union. Immunotherapy remains experimental. Drugs in advanced clinical development include the programmed death 1 antibody, nivolumab, the antibody drug conjugate depatuxizumab directed to the epidermal growth factor receptor and the proteasome inhibitor marizomib.
Definition anD Diagnosis
The diagnosis of glioblastoma requires the histological and molecular genetic study of tumour tissue obtained during open tumour resection or biopsy. Morphologically, glioblastoma is defined as a glial brain tumour with features of malignancy that include angiogenesis and focal necrosis. The new WHO classification recognises, in addition to classical glioblastoma, giant cell glioblastoma, gliosarcoma and epithelioid glioblastoma as histologically defined variants. Half of the rare epithelioid glioblastomas show BRAF V600E mutations. 1 So far treatment recommendations do not vary for these glioblastoma variants.
Furthermore, classical glioblastoma does not exhibit isocitrate dehydrogenase (IDH) 1 or 2 mutations; tumours carrying such mutations show a less aggressive clinical course and will probably no longer be labelled glioblastomas in future revisions of the WHO classification. In contrast, it has been proposed to consider glial tumours without IDH 1 or 2 mutations which do not fulfil histological criteria of glioblastoma as tumours equivalent to glioblastoma, for example, in the context of a clinical trial if they fulfill one of the following criteria: epidermal growth factor receptor amplification, whole chromosome 7 gain combined with whole chromosome 10 loss or telomerase reverse transcriptase promoter mutation. 2 Specifically in glioblastoma without IDH mutation and thus commonly without CpG island methylator phenotype, methylation of the promoter region of the O 6 -methylguanine DNA methyltransferase (MGMT) gene, tested by methylation-specific PCR or by pyrosequencing, has been established as a predictive biomarker for benefit from alkylating agent chemotherapy. Extensive efforts have been undertaken to define cut-offs to dissect what extent of MGMT promoter methylation is required to confer benefit from alkylating chemotherapy and which CpG of the promoter region should be assessed. With methylation-specific PCR, there is a grey zone in between truly unmethylated and methylated, resulting in a recommendation of a cut-off of 1.27 (Log2 (1000×(MGMT+1)/ACTB) plus a safety margin of −0.28). With pyrosequencing, the cut-off for being methylated is usually set at 7%-25%. 3 Young age and good performance status are therapy-independent positive prognostic factors. Figure 1 provides an algorithm how to approach glioblastoma that is consistent with the 2017 guideline of the European Association of Neuro-Oncology. 4 newly DiagnoseD setting surgery Maximum surgical resection using microsurgical techniques as safely feasible is considered standard of care, although the role of surgery has been difficult to define in controlled clinical trials. The proof-ofconcept trial for fluorescence-guided resection indicated improved progression-free survival in patients who had a gross total resection. 5 The extent of surgery should be verified by contrast-enhanced MRI within 24-72 hours of surgery. Although the volume of residual tumour after surgery negatively correlates with outcome, it has remained impossible to clarify whether extent of resection improves outcome or whether tumours amenable to gross total resection have a different, less malignant course of disease. Still, we support efforts at gross total tumour resection and do not believe that a randomised clinical trial to demonstrate benefit from this intervention can be ethically justified. If microsurgical resection is not feasible due to medical reasons or refusal of the patient, an image-guided stereotactic serial biopsy can provide sufficient material for both histological as well as molecular diagnosis to guide therapeutic management. 6 Some centres prefer open biopsies to get more tissue. Treatment decisions without obtaining tissue for a histological diagnosis are strongly discouraged. 9 10 Limitations include major comorbidities such as haematological or hepatic disease or infection. Myelosuppression, notably thrombocytopenia, is the most common side effect. There is no evidence that changing the dosing of the temozolomide regimen or prolonging its administration beyond 6 months improve survival. 4 Benefit from temozolomide is largely restricted to patients with tumours with MGMT promoter methylation. 12 While this treatment is safe and usually well tolerated except for local skin reactions, its acceptance by patients, relatives and healthcare professionals in most parts of Europe is low. Furthermore, reimbursement remains a critically debated issue in most countries.
Best supportive care
This strategy may be selected for patients with extensive or multifocal lesions in poor general or neurological condition and patients who cannot consent to further treatment once the diagnosis of glioblastoma has been established.
ReCuRRent setting
Standards of care at recurrence are far less well defined than in the newly diagnosed setting. Up to half of patients with glioblastoma may not qualify for salvage treatment. 13 Repeat surgery should be offered if a gross total resection seems feasible and if the time from first surgical intervention is longer than approximately 6 months.
14 Reirradiation can be offered to patients with circumscribed recurrences. Neither for surgery nor for radiotherapy, a randomised trial to document prolongation of survival has been conducted. Tumour-treating fields were not superior to best physicians' choice in the recurrent setting.
Most patients with recurrent glioblastoma who are eligible for salvage therapy are treated with a second course of alkylating agent chemotherapy, mostly lomustine (CCNU). The strategy of temozolomide rechallenge is less frequently pursued today than a few years ago. Either alkylating agent is unlikely to provide benefit in patients with tumours without MGMT promoter methylation. Bevacizumab as a single agent was approved in the USA and various other countries, although not the European Union, based on response rates and progression-free survival rates at 6 months interpreted to be superior to historical controls. Yet, the combination of bevacizumab with lomustine prolonged progression-free survival only, but not overall survival, compared with lomustine alone. 15 The differential interpretation of the significance and validity of progression-free survival explains the different approval status of bevacizumab in recurrent glioblastoma. Depending on local availability, the combination of bevacizumab and lomustine is a treatment option in particular in patients with rapidly progressing disease. Much more commonly, bevacizumab where available is now used in symptomatic patients at later recurrences. A population-based analysis has not been able to find evidence that the approval of bevacizumab prolonged survival on a population level. 13 follow-uP Neurological evaluation and MRI at least every 3 months are the central tools to assess benefit from therapy and for monitoring during follow-up. Pseudoprogression remains a concern especially within the first 3-6 months after completion of radiotherapy. Advanced MRI and positron emission tomography are explored to provide guidance, but the most important consideration in patients with potential pseudoprogression is not to discontinue a potentially active treatment too early. Throughout the course of disease, control of symptomatic seizures and detection, treatment and secondary prevention of venous thromboembolic events remain important tasks. Primary seizure prophylaxis with antiepileptic drugs is not indicated and steroids should be given to symptomatic patients only, at the lowest dose and for the shortest time feasible.
CuRRent DeveloPments
Data from four phase III trials may change clinical practice in the upcoming years. CheckMate 498 (NCT02617589) and CheckMate 548 (NCT02667587) explored nivolumab in newly diagnosed patients with glioblastoma without and with MGMT promoter methylation. Depatuxizumab, an antibody drug conjugate, was tested in the same setting in estimated glomerular filtration rate-amplied glioblastoma (NCT02573324). These trials have completed accrual and data should become available in 2019. The proteasome inhibitor marizomib is examined in newly diagnosed glioblastoma within the European Organisation for Research and Treatment of Cancer trial 1709 (NCT03345095).
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